Back to Market Feed

Product Information

REPATHA 140 MG/ML SYRINGE is a brand product labeled by Amgen Inc., priced at $281.8058 per ML under NDC 72511050101. Its NADAC has been published 77 times since Mar 5, 2025.

REPATHA 140 MG/ML SYRINGE

Evolocumab
$281.8058per ML

Strength

140 mg/mL

Manufacturer

Amgen Inc.

NDC

72511050101

Classification

Brand

Dosage Form

INJECTION, SOLUTION

Route

SUBCUTANEOUS

Effective Date

8/19/2026

Active Ingredients

EVOLOCUMAB

Approval Type

Biologic (BLA)

FDA Application

BLA125522

On Market Since

11/24/2024

Pharmacological Classes

Antibodies
Monoclonal
PCSK9 Inhibitor
PCSK9 Inhibitors

Price Statistics

The NADAC for REPATHA 140 MG/ML SYRINGE has been published 77 times since Mar 5, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.

Current price$281.8058 per ML
All-time high$281.9135 (Jun 10, 2026)
All-time low$275.4546 (May 21, 2025)
52-week high$281.9135
52-week low$275.6225
Median price$276.2991
Average price$278.1744
Largest weekly change+2.0% (Jan 14, 2026)
Weeks tracked77
Tracking sinceMar 5, 2025

Price History

1W

+0.0%

1M

+0.0%

3M

-0.0%

6M

+0.2%

1Y

+2.2%

3Y

N/A

5Y

N/A

All

+2.0%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

1 alternative • Same active ingredient

REPATHA 140 MG/ML SYRINGE
Brand
72511075001•Amgen Inc.
$281.8058

Related Drugs

Same classification

PRALUENT 75 MG/ML PEN
Brand
61755002002•Regeneron Pharmaceuticals, Inc.
$257.7315
per ML
PRALUENT 150 MG/ML PEN
Brand
61755002102•Regeneron Pharmaceuticals, Inc.
$258.0245
per ML
DUPIXENT 300 MG/2 ML PEN
Brand
00024591502•Sanofi-Aventis U.S. LLC
$1009.1638
per ML
DUPIXENT 300 MG/2 ML SYRINGE
Brand
00024591401•Sanofi-Aventis U.S. LLC
$1011.3804
per ML
DUPIXENT 200 MG/1.14 ML SYRING
Brand
00024591801•Sanofi-Aventis U.S. LLC
$1773.2433
per ML
DUPIXENT 200 MG/1.14 ML PEN
Brand
00024591902•Sanofi-Aventis U.S. LLC
$1778.2754
per ML

Frequently asked questions

What is the NADAC price of REPATHA 140 MG/ML SYRINGE?

The current National Average Drug Acquisition Cost (NADAC) for REPATHA 140 MG/ML SYRINGE, manufactured by Amgen Inc., is $281.8058 per ML (NDC 72511050101), effective Aug 19, 2026.

How has the price of REPATHA 140 MG/ML SYRINGE changed over time?

Over the history we have for it, the NADAC for REPATHA 140 MG/ML SYRINGE has held within roughly two percent of its current level. It has been tracked across 77 weekly CMS publications since Mar 5, 2025.

What are the highest and lowest recorded NADAC prices for REPATHA 140 MG/ML SYRINGE?

Since Mar 5, 2025, the NADAC for REPATHA 140 MG/ML SYRINGE has ranged from a low of $275.4546 (May 21, 2025) to a high of $281.9135 (Jun 10, 2026), with a median of $276.2991 per ML.

Are there cheaper alternatives to REPATHA 140 MG/ML SYRINGE?

1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as REPATHA 140 MG/ML SYRINGE in a comparable dosage form, but none are currently priced below it.

Who manufactures REPATHA 140 MG/ML SYRINGE?

REPATHA 140 MG/ML SYRINGE (NDC 72511050101) is labeled by Amgen Inc., and CMS classifies it as a brand product.